About the PCCNC
Mission
Membership
Sponsors
Legislation
Prostate Cancer
Risk Reduction
Symptoms
Early Detection
Practice Guidelines
Patient Tools
Understanding Diagnosis
Researching Treatments
Support Groups
Cancer Centers
Clinical Trials
Financial Programs
Caregiver Resources
In the News
|
|
Committee Portals: Public Awareness | Early Detection | Patient Care and Support | Home
NC Insurance Statutes
print friendly version of this page |
Statutes
§ 58-50-155. Standard and basic health care plan coverages.
(a)Notwithstanding G.S. 58-50-125(c), the standard health
plan developed and approved under G.S. 58-50-125 shall provide
coverage for all of the following:
(1) Mammograms and pap smears at least equal to the
coverage required by G.S. 58-51-57.
(2) Prostate-specific antigen (PSA) tests or equivalent
tests for the presence of prostate cancer at least
equal to the coverage required by G.S. 58-51-58.
§ 58-51-58. Coverage for prostate-specific antigen (PSA)
tests.
(a)Every policy or contract of accident and health
insurance, and every preferred provider benefit plan under G.S.
58-50-56, that is issued, renewed, or amended on or after January
1, 1994, shall provide coverage for prostate-specific antigen
(PSA) tests or equivalent tests for the presence of prostate
cancer. The same deductibles, coinsurance, and other limitations
as apply to similar services covered under the policy, contract,
or plan shall apply to coverage for prostate-specific antigen
(PSA) tests or equivalent tests for the presence of prostate
cancer.
(b) As used in this section, "prostate-specific antigen (PSA)
tests or equivalent tests for the presence of prostate cancer"
means serological tests for determining the presence of prostate
cytoplasmic protein (PSA) and the generation of antibodies to it,
as a novel marker for prostatic disease.
(c) Coverage for prostate-specific antigen (PSA) tests or
equivalent tests for the presence of prostate cancer shall be
provided when recommended by a physician. (1993, c. 269, s. 1;
1997-519, s. 3.4.)
§ 58-65-93. Coverage for prostate-specific antigen (PSA)
tests.
(a)Every insurance certificate or subscriber contract
under any hospital service plan or medical service plan governed
by this Article and Article 66 of this Chapter, and every
preferred provider benefit plan under G.S. 58-50-56, that is
issued, renewed, or amended on or after January 1, 1994, shall
provide coverage for prostate-specific antigen (PSA) tests or
equivalent tests for the presence of prostate cancer. The same
deductibles, coinsurance, and other limitations as apply to
similar services covered under the certificate or contract shall
apply to coverage for prostate-specific antigen (PSA) tests or
equivalent tests for the presence of prostate cancer.
(b) As used in this section, "prostate-specific antigen (PSA)
tests or equivalent tests for the presence of prostate cancer"
means serological tests for determining the presence of prostate
cytoplasmic protein (PSA) and the generation of antibodies to it,
as a novel marker for prostatic disease.
(c) Coverage for prostate-specific antigen (PSA) tests or
equivalent tests for the presence of prostate cancer shall be
provided when recommended by a physician. (1993, c. 269, s. 2;
1997-519, s. 3.7.)
§ 58-67-77. Coverage for prostate-specific antigen (PSA)
tests.
(a)Every health care plan written by a health maintenance
organization and in force, issued, renewed, or amended on or
after January 1, 1994, that is subject to this Article, shall
provide coverage for prostate-specific antigen (PSA) tests or
equivalent tests for the presence of prostate cancer. The same
deductibles, coinsurance, and other limitations as apply to
similar services covered under the plan shall apply to coverage
for prostate-specific antigen (PSA) tests or equivalent tests for
the presence of prostate cancer.
(b) As used in this section, `prostate-specific antigen (PSA)
tests or equivalent tests for the presence of prostate cancer'
means serological tests for determining the presence of prostate
cytoplasmic protein (PSA) and the generation of antibodies to it,
as a novel marker for prostatic disease.
(c) Coverage for prostate-specific antigen (PSA) tests or
equivalent tests for the presence of prostate cancer shall be
provided when recommended by a physician. (1993, c. 269, s. 3.)
copyright notice
disclaimer
Prostate Cancer Coalition of North Carolina (PCCNC) 5905 Shamrock Road Research Triangle Park, NC 27713 919.321.0365 email
About PCCNC
Awareness | Prostate Cancer 101 | Risk Factors | Prevention | Statistics
Early Detection | Prostate Screening | The PSA Blood Test | The Digital Exam (DRE)
NC Insurance Statutes | Screening Locations | Referral Guidelines | Diagnostic Tools
Patient Resources | Understanding Diagnosis | Support Groups | Cancer Centers | Clinical Trials | Treatment
Advocate Tools | Presentations | Handouts | Gift Items
Volunteer | Donate | In the News | Calendar | Legislative Advocacy
Medical Professionals | Minority Communities | Partners & Caregivers
|